Regeneron Pharmaceuticals (REGN): Initiation of Coverage (FY2023-FY2025, Q2 2026 LTM)
Key Points
- Growth Engines: Regeneron grew revenue from $13.1B in FY2023 to $14.3B in FY2025 and returned to double-digit growth in 2026 (+17% YoY in Q2 2026), driven by Dupixent, EYLEA HD, and Libtayo. Dupixent global net sales reached $6.0B in Q2 2026 (+38% YoY), with continued robust demand across all indications and geographies.
- Product Transition: EYLEA HD has overtaken legacy EYLEA in U.S. net sales as of Q2 2026, now accounting for over 60% of the U.S. retina franchise. However, legacy EYLEA faces steep declines (-45% YoY in Q2 2026) due to biosimilar competition and conversion to EYLEA HD.
- Pipeline & R&D: The company maintains a deep and diversified pipeline (~45 clinical programs), with late-stage assets in complement-mediated diseases, obesity, oncology, and next-generation immunology. R&D investment has increased significantly, reaching $5.85B in FY2025.
- Profitability & Capital Returns: Net income rose from $3.95B in FY2023 to $4.50B in FY2025, with diluted EPS increasing from $34.77 to $41.48. Regeneron initiated a quarterly dividend in 2025 ($0.88/share, increased to $0.94/share in early 2026) and continued aggressive share repurchases.
- Balance Sheet Strength: As of Q2 2026, Regeneron reported $15.1B in cash and marketable securities net of debt, supporting ongoing R&D, business development, and capital returns.
- Risks: Key risks include heavy dependence on a few blockbuster products, accelerating biosimilar competition (notably for EYLEA), regulatory/manufacturing challenges, and ongoing legal/regulatory investigations.
Business Overview
Regeneron is a fully integrated biotechnology company focused on inventing, developing, manufacturing, and commercializing medicines for serious diseases. Its portfolio spans ophthalmology (EYLEA, EYLEA HD), immunology (Dupixent, Kevzara), oncology (Libtayo, Lynozyfic, Ordspono), cardiovascular/metabolic, rare diseases, and infectious diseases. The company operates as a single business segment and collaborates with Sanofi and Bayer for development and commercialization of key products.
Financial Snapshot: Fiscal Years Ended December 31 ($M except per share)
| Fiscal Year | Revenue | Net Income | Diluted EPS | R&D Expense | Operating Margin* | Cash & Equiv. | LT Debt | Dividend/Share | Shares Repurchased (M) |
|---|
| 2025 | 14,342.9 | 4,504.9 | 41.48 | 5,850.2 | 24.9% | 3,118.1 | 1,985.9 | $0.88/qtr | 5.6 |
| 2024 | 14,202.0 | 4,412.6 | 38.34 | 5,132.0 | 28.1% | 2,488.2 | 1,984.4 | - | 2.8 |
| 2023 | 13,117.2 | 3,953.6 | 34.77 | 4,439.0 | 30.9% | 2,730.0 | 2,014.7 | - | 2.9 |
*Operating margin calculated as income from operations/revenue.
Quarterly Snapshot: Key Metrics (Q3 2025-Q2 2026)
| Quarter | Total Revenue ($B) | YoY Growth | Non-GAAP EPS ($) | Non-GAAP Net Income ($B) | Dupixent Global Net Sales ($B) | EYLEA HD US Net Sales ($M) | Libtayo Global Net Sales ($M) | Cash & Marketable Securities less Debt ($B) | Share Repurchases ($B, YTD) |
|---|
| Q2 2026 | 4.3 | +17% | 14.29 | 1.5 | 6.0 | 596 | 489 | 15.1 | 2.0 |
| Q1 2026 | 3.6 | +19% | 9.47 | 1.0 | 4.9 | 468 | 438 | 15.8 | 0.8 |
| Q4 2025 | 3.9 | +3% | 11.44 | 1.2 | 4.9 | 506 | 425 | 16.2 | 3.4 (FY) |
| Q3 2025 | 3.8 | +1% | 11.83 | 1.3 | 4.9 | 431 | 365 | 16.0 | 2.8 (YTD) |
Segment/Product Sales Breakdown: FY Ended December 31 ($M)
| Product | 2025 (US) | 2025 (ROW) | 2025 (Total) | 2024 (US) | 2024 (ROW) | 2024 (Total) | 2023 (US) | 2023 (ROW) | 2023 (Total) |
|---|
| EYLEA HD | 1,636.9 | 932.7 | 2,569.6 | 1,201.1 | 239.9 | 1,441.0 | 165.8 | - | 165.8 |
| EYLEA | 2,747.8 | 2,573.6 | 5,321.4 | 4,767.1 | 3,336.9 | 8,104.0 | 5,719.6 | 3,495.2 | 9,214.8 |
| Dupixent (Global) | - | - | 17,806.7* | - | - | 14,148.0* | - | - | 11,588.1* |
| Libtayo | 944.7 | 507.5 | 1,452.2 | 787.3 | 429.5 | 1,216.8 | 538.8 | 330.0 | 868.8 |
| Praluent | 262.5 | 594.3 | 856.8 | 241.7 | 523.3 | 765.0 | 182.4 | 456.5 | 638.9 |
| Kevzara | 371.4 | 203.2 | 574.6 | 270.2 | 188.5 | 458.7 | 214.7 | 171.2 | 385.9 |
| Other Products | 210.0 | 113.3 | 323.3 | 202.9 | 90.0 | 292.9 | 150.5 | 686.2 | 836.7 |
*Dupixent global net product sales are recorded by Sanofi; Regeneron records its share of profits.
Key Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|
| Revenue +17% YoY in Q2 2026; diluted EPS up from $34.77 (FY2023) to $41.48 (FY2025) | Heavy dependence on EYLEA HD, EYLEA, and Dupixent for revenue and profit |
| Robust pipeline with ~45 clinical candidates, including multiple late-stage programs | EYLEA U.S. sales declined 42% YoY in FY2025 due to biosimilar competition |
| Significant R&D investment supporting future innovation | Increasing biosimilar launches expected in U.S. and globally in 2026 |
| Initiation of quarterly dividend and ongoing share repurchases | Ongoing legal and regulatory risks, including DOJ investigations and patent litigation |
| High profitability and strong cash position ($3.1B cash, $18.9B in financial assets at FY2025) | Gross margin on net product sales decreased to 82% in FY2025 (from 86% in FY2024) |
| Expanding international presence and new product launches (e.g., Lynozyfic, Ordspono in EU) | High customer concentration: two customers accounted for 77% of gross product revenue in FY2025 |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|
| Launch and uptake of EYLEA HD pre-filled syringe | Additional biosimilar EYLEA launches in U.S. (expected H2 2026) |
| Expansion of Dupixent into new indications (e.g., bullous pemphigoid, AFRS) | Further declines in EYLEA U.S. sales due to payer pressure or biosimilars |
| New product launches in oncology and rare diseases (e.g., Lynozyfic, Ordspono) | Adverse outcomes in ongoing DOJ or patent litigation |
| Progress on pipeline milestones (e.g., fianlimab, garetosmab, DB-OTO) | Delays or negative results in key late-stage clinical trials |
| International expansion and successful commercialization outside U.S. | Regulatory or reimbursement headwinds in major markets |
| Continued capital returns (dividends, buybacks) | Manufacturing or supply chain disruptions |
Top Questions to Ask Before Investing
- How will Regeneron offset the sharp decline in EYLEA U.S. sales as biosimilar competition intensifies in 2026 and beyond?
- Can EYLEA HD adoption and new indications meaningfully compensate for legacy EYLEA erosion?
- What is the long-term growth outlook for Dupixent, and how sustainable is its competitive advantage in core indications?
- How robust is the late-stage pipeline, and which upcoming readouts or approvals could materially impact the revenue mix?
- What is the risk of adverse outcomes from ongoing DOJ investigations, patent litigation, or pricing reforms?
- How will Regeneron manage gross margin pressures and maintain high profitability amid product mix shifts and increased competition?
- What is the company's strategy for capital allocation, especially regarding dividends, buybacks, and potential M&A?
- How exposed is Regeneron to customer concentration risk, and what steps are being taken to diversify the revenue base?
- What are the key operational risks in manufacturing, supply chain, and international expansion?
- How will changes in U.S. and international drug pricing and reimbursement policies affect Regeneron's top-line and bottom-line growth?
Conclusion:
Regeneron enters the next phase with strong commercial momentum in Dupixent, EYLEA HD, and Libtayo, a deep and advancing pipeline, and significant financial flexibility. The company’s ability to navigate biosimilar headwinds, execute on pipeline milestones, and manage regulatory/manufacturing risks will be critical to sustaining its growth trajectory and defending its leadership in biologics and genetic medicines.
